Related Experiment Video

Updated: Jun 14, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Small tumor size and node-negative HER2-positive breast cancer: a step forward for a better treatment?

Diana Crivellari, Annamaria Molino

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |April 7, 2010
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
    09:29

    Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

    Published on: March 20, 2020

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
    11:49

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

    Published on: April 3, 2026

    Related Experiment Videos

    Last Updated: Jun 14, 2026

    Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
    14:20

    Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

    Published on: June 13, 2014

    Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
    09:29

    Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

    Published on: March 20, 2020

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
    11:49

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

    Published on: April 3, 2026

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Usefulness of Left Atrial Remodeling in Predicting CardiacToxicity During Trastuzumab Therapy for Breast Cancer.

    The American journal of cardiology·2018

    Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity.

    Clinical cardiology·2018

    The involvement of early stage breast cancer patients during oncology consultations in Italy: a multi-centred, randomized controlled trial of a question prompt sheet versus question listing.

    BMJ open·2017

    Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

    The oncologist·2017

    Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.

    Minerva cardioangiologica·2016

    A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.

    Future oncology (London, England)·2016

    Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Weight Loss without Food Intake Suppression through Size-Dependent Retention of Anti-Inflammatory Nanomedicines.

    ACS nano·2026

    Spectral-Proteomic Integration Analysis (SPIA) Deciphers Molecular Trajectories of Breast Cancer and Enables Multitarget Therapeutic Assessment.

    Analytical chemistry·2026

    The Efficacy of Different Treatment Options in Cutaneous Sarcoidosis: A Meta-analysis of RCTs.

    Acta dermato-venereologica·2026

    Synergistic antifungal activity and mechanisms of dehydronuciferine combined with fluconazole against drug-resistant Candida albicans.

    Microbiology spectrum·2026

    Uracil-Quinazoline Hybrids: Cytotoxicity, Docking, MD, and DFT Studies.

    Medicinal chemistry (Shariqah (United Arab Emirates))·2026

    Emerging Therapies in Lung Cancer: A Review on Targeted and Immune Based Interventions.

    Current drug discovery technologies·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us